That's a good point. Precision appears to be the name of the game with the device and so it makes sense that they wouldn't leave pitch matching and calibration up to the end user.
I question whether you would even be able to determine or match your pitch by yourself. I also wonder how pitch matching is done. Is it when you can't hear your tinnitus pitch? Because I can't hear a whole slew of frequencies.
???
Buddy, the clinical trial is going on. When the device is approved and goes to market you can ask all these questions, but killing them with so many questions now while it is going through the clinical trial, for me, makes no sense.
I'm not asking the researchers questions though, I'm asking people here questions. I was asking people here about how pitch matching is supposed to work, especially considering that people here have difficulty with doing it. Like, take into consideration the actual post you're responding to. Where in the post you're quoting did I mention the researchers or say I would ask them anything?
Hard Agree. This is why academics, researchers, companies, CEOs, etc, setup Q&A events or interviews with people like those running the TinnitusTalk Podcast. They are establishing an appropriate forum for potential patients / customers / doctors / investors, etc to ask questions and get qualified answers. Let's show them some respect and not blast them via email, tweet at them, or utilize any other pedestrian means to bother them. The field they're working in (hearing loss / tinnitus / hyperacusis) is already EXTREMELY underfunded and under-researched given its prevalence (MILLIONS) and duration (since recorded history of mankind), let's not scare away or disenfranchise the small cohort of people who can actually move science / commercialization towards a useable treatment.
What is the definition of well-distributed? Lenire is available in about 100 clinics in England, Belgium, Germany, Switzerland, Austria, and Ireland. If the product wasn't successful at all we wouldn't see it in that many clinics.
Technology is TOTALLY different. Lenire targets no DCN or Fusiform cells. It is just a habituation device. It is a marketing scam basically. Theranos Mark II.
Just goes to show how much demand there is for a treatment, even one that is at best modestly better than placebo, and how quickly the existing audiological infrastructure can accommodate the distribution of a product when it becomes available. Imagine how fast audiologist offices will line up to sell a device that is actually effective. Imagine how great it would feel as a medical professional to finally be able to decrease people's suffering while raking in the bucks.
April is primary completion date. Analysing data, report etc will take some months...!
I don't think that is the case. Primarily they would like frequency matching, but keep in mind that you don't know the frequency of tinnitus in guinea pigs either. They just went with 8 kHz because this is the most common tone. They don't know if guinea pigs have one sound, multiple sounds, hissing, etc. It might take some trial and error once the device is released. There was no trial inclusion criteria for pure tone tinnitus either.
We'll see. I read that they won't be unblinding till the end of the study, but hopefully it won't be too long to get the headline data thereafter. I would imagine the data is sitting there clean as can be waiting for the unblinding to attach the one last attribute to the data lines.
Isn't she a speaker at the Tinnitus Research Initiative in Vancouver at the end of June?
How do they know it worked on guinea pigs? Let me guess, the guinea pigs were more happy in life.
Good to know - thanks for the efforts. I hope this speeds things up by not having to build a distributor/retail network but becoming a standard treatment for tinnitus which can be initiated by an ENT. Downside for us in Europe that EMA approval might be required which is not spoken of as of yet...
Member
